Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

doi:10.4254/wjh.v7.i9.1287

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6632)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

443

WORD

261

HTML

2506

Figures (1-2)

207

Tables (1-5)

168

Sum=3585

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1105

Download

1942

Sum=3047

May 28, 2015 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. May 28, 2015; 7(9): 1287-1296
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1287

Table 2 Treatment response

	Sustained virological response												Treatment failure
	Pat. 1	Pat. 2	Pat. 3	Pat. 4	Pat. 5	Pat. 6	Pat. 7	Pat. 8	Pat. 9	Pat. 10	Pat. 11	Pat. 12	Pat. 13	Pat. 14	Pat. 15	Pat. 16	Pat. 17	Pat. 18	Pat. 19	Pat. 12
HCV GT	1b	1b	1a	1b	1b	1b	1b	1b	1b	1a	1b	1a	1a	1a	1b	1a	1b	1a	1b	1a
Basline	2763000	4860000	1183000	5758000	1713000	1950000	441000	14900000	1920000	456000	387700	10900000	11500000	1008000	2565000	1690000	1370000	135600	580400	10900000
TW 4 (RVR)	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	71	37	34	< Q	< Q	15	4668	< Q
TW 12 (EVR)	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	685	< Q	< Q	3322000	< Q	< Q	6848	< Q
TW 16	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	371	< Q	< Q	ND	6260	ND	ND	< Q
TW 24	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	164	466	55400	ND	ND	ND	ND	< Q
TW 48					< Q	< Q	< Q	< Q	< Q	< Q	< Q
12 wk pt	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	457200	9704	1657	1564794	ND	966400	27	660300	457200
24 wk pt	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	< Q	691400	4135000		3735000	ND	7420000	9824	3489000	691400

HCV: Hepatitis C virus; TW: Treatment weeks; GT: Genotype; RVR: Rapid virological response; EVR: Early viral response; pt: Post treatment; Pat: Patient; ND: Not determined.

Citation: Herzer K, Papadopoulos-Köhn A, Achterfeld A, Canbay A, Piras-Straub K, Paul A, Walker A, Timm J, Gerken G. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol 2015; 7(9): 1287-1296
URL: https://www.wjgnet.com/1948-5182/full/v7/i9/1287.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i9.1287